SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

USFDA conducts cGMP audit at Cipla’s Indore formulations facility

17 Apr 2018 Evaluate

The US Food and Drug Administration (USFDA) has conducted a routine current Good Manufacturing Practices (cGMP) audit at Cipla’s Indore formulations facility from April 2, 2018 till April 13, 2018. This was in the normal course of business. There were no data integrity and/or repeat observations.

The company believes the observations are unlikely to have any material adverse impact and it will submit the response within the stipulated timeframe.

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients. The company’s portfolio includes over 1500 products across wide range of therapeutic categories with one quality standard globally.


Cipla Share Price

1294.75 -11.10 (-0.85%)
24-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1619.95
Dr. Reddys Lab 1315.85
Cipla 1294.75
Zydus Lifesciences 927.15
Lupin 2296.10
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×